Inborn errors of purine metabolism are rare syndromes with an array of complex phenotypes in 23 humans. One such disorder, adenylosuccinate lyase deficiency (ASLD), is caused by a decrease in the 24 activity of the bi-functional purine biosynthetic enzyme, adenylosuccinate lyase (ADSL). Mutations in 25 human ADSL cause epilepsy, muscle ataxia, and autistic-like symptoms. Although the genetic basis of 26 ASLD syndrome is known, the molecular mechanisms driving phenotypic outcome are not. Here, we 27 characterize neuromuscular and reproductive phenotypes associated with a deficiency of adsl-1 in 28
Introduction 56
Inborn errors of purine metabolism are understudied syndromes that arise from mutation of 57 purine biosynthetic or catabolic enzymes. Although rare, these disorders are thought to be underdiagnosed 58 because the varied clinical symptoms mimic other disorders (1). Purine disorders can have devastating 59 health effects and often result in early death. Not only are there few therapeutic options available to 60 patients, but the intriguing biological mechanisms linking defects in purine biosynthesis to phenotypic 61
outcomes have also been difficult to decipher. Our aim is to use a fast, inexpensive and yet applicable 62 model to explore the molecular links between perturbations in purine biosynthesis and organismal 63 physiological and behavioral outcomes and to generate therapeutic strategies for these rare and 64 understudied syndromes. 65
Purine nucleotides are monomers that polymerize with pyrimidine nucleotides to form nucleic 66 acids. They also serve critical roles in cell signaling, energy storage and transfer, and metabolic regulation 67
(2). Purines are synthesized via two biosynthetic pathways: de novo and salvage. De novo purine 68 biosynthesis forms purine monomers from the components of intracellular amino acids and sugars. This 69 pathway takes eleven steps to convert ribose-5-phosphate (R5P) to inosine monophosphate (IMP), the 70 precursor for other purine monomers (Fig 1) . The salvage biosynthetic pathway uses nucleic acid 71 constituents from the diet or purine catabolism to create new purine products. 72
Adenylosuccinate lyase (ADSL) is an enzyme with dual functions in de novo purine biosynthesis. 73
It catalyzes the cleavage of succinyl groups to yield fumarate twice in de novo synthesis; it converts 74 succinylaminoimidazole carboxamide ribotide (SAICAR) to aminoimidazole carboxamide ribotide 75 (AICAR) and succinyladenosine monophosphate (S-AMP) to adenosine monophosphate (AMP). 76
Adenylosuccinate lyase deficiency (ASLD) is a human syndrome associated with a spectrum of 77 symptoms including seizures, ataxia, cognitive impairment, and autistic-like behaviors (3-5). Symptoms 78 range in severity from mild to severe and are negatively correlated with the degree of residual ADSL 79 activity (6). In the most extreme cases, ASLD is neonatally fatal due to prenatal growth restriction, 80 encephalopathy, and intractable seizures (6,7). This autosomal recessive neurometabolic disorder has 81 been reported in over 50 patients since its original characterization in 1969; for these cases, over 40 82 separate mutations in adenylosuccinate lyase (ADSL) are associated with the disease state (8-10). 83
There are competing hypotheses about the etiology of ASLD symptoms. Severity of symptoms 84 has been positively correlated with the level of accumulation of two succinylnucleosides, SAICAr and S-85
Ado, in the urine and cerebrospinal fluid (9,11). These nucleosides are the dephosphorylated forms of the 86 ADSL substrates SAICAR and S-AMP, respectively, and their accumulation in body fluids is the only 87 biochemical marker of the disorder. Previous findings associated a lower ratio of S-Ado/SAICAr with 88 more severe symptoms, and it was hypothesized that S-Ado is protective while SAICAr is toxic (9,11). 89
Recent findings indicate that this ratio is not predictive of phenotype severity, but correlates to the 90 patient's development and age during sample collection (6). Dephosphorylation of SAICAR to SAICAr 91 has also been proposed to be a detoxification mechanism to reduce the toxic accumulation of SAICAR in 92 affected cells (12). Thus, questions remain about the role of ADSL substrates in disease etiology. 93
It is also hypothesized the blockage of purine biosynthesis specifically contributes to ASLD 94 symptoms. Deficiency of ADSL is expected to result in decreased concentrations of purine products, 95 particularly adenine nucleotides, due to the dual function of this enzyme in the biosynthesis of AMP. 96
However, no deficit in purines has been detected in patients; measurements of purine levels in kidney, 97 liver, and muscle cells of ASLD patients are normal (13). Residual activity in patients likely contributes 98 to the conservation of purine levels. Measurements of ADSL enzyme activity indicate that 3% residual 99 activity is sufficient to convert S-AMP to AMP; although metabolic flux is greatly hindered (13). 100
Moreover, a reduction in ADSL activity can be circumvented via supply of purines through the salvage 101 pathway and dietary intake (14). In this case, affected cells and tissues would be dependent on high 102 activities of the salvage enzymes to maintain purine levels. It remains possible that a deficit in the ability 103 to synthesize purines de novo at a specific developmental stage contributes to phenotypic outcome, but 104 evidence in support of these hypotheses to explain ADSL phenotypes is still lacking. 105
Neither adsl-1(tm3328) mutants nor animals exposed to RNAi of adsl-1 for their whole life cycle 139 are capable of producing progeny (n>100). Compared to N2 strain control animals, the gonad arms of 140 adsl-1(tm3328) adults appear deformed, severely shrunken, and lack any indication of mature germ cell 141 production (S1 Fig) , indicating a requirement for adsl-1 in normal gonadogenesis. To reveal processes 142 that may require adsl-1 function acutely, we also exposed fertile egg-laying adult animals in their first day 143 of egg-laying to RNAi. Within 24 hours, these animals display an array of phenotypes. We observed both 144 germ cells in the proximal gonad and oocytes in double file as opposed to single file in the proximal 145 gonad, indicating abnormal progression of oogenesis (Fig 2) . Deterioration of gonad arms was also 146 evident (Fig 2, S2 Fig) . We conclude that adsl-1 is required for normal development of the gonad and is 147 required acutely for maintenance of normal oogenesis. 148
Animals exposed to adsl-1(RNAi) starting in the mid-fourth larval stage produce early offspring 149 that can be phenotypically examined. We observed a high degree of embryonic lethality (18%) in these 150 offspring ( Fig 3A) . Thus, not only is oogenesis hindered when adsl-1 function is decreased, but 151 embryonic development is disrupted as well. We also examined the adsl-1(tm3328) mutant strain for 152 evidence of developmental lethality. The sterility of the adsl-1(tm3328) strain requires the strain to be 153 maintained using a balancer chromosome. Because the hT2 balancer is homozygous lethal, a genotypic 154 ratio of one adsl-1(tm3228) homozygote for every two balanced heterozygotes should segregate from the 155 balanced heterozygote. However, only 16% of the progeny of balanced heterozygotes were homozygous 156 adsl-1(tm3328/tm3328) mutants ( Fig 3B) . This altered genotypic ratio of one homozygote for every 5.3 157 heterozygotes indicates that 62% of the adsl-1(tm3328/tm3328) population is missing. We conclude that 158 there is a developmental lethality for the homozygous mutants, similar to the embryonic lethality of adsl-159 1(RNAi). 160 161
Disruption of adsl-1 function results in neuromuscular defects 162
adsl-1(tm3328) and adsl-1(RNAi) animals are noticeably sluggish compared to control animals. 163
We quantified crawling speed of adsl-1(tm3328), demonstrating that they have severely slowed 164 locomotion ( Fig 4A) . Upon transfer to liquid, C. elegans will continually thrash for over 90 minutes 165 before alternating to periods of inactivity (25). We also manually counted the thrashing rate during this 166 active period as an indication of body wall muscle function. Thrashing rate is reduced for both adsl-167 1(tm3328) and adsl-1(RNAi) animals; mutants and RNAi animals exhibit a 77% and 22% reduction in 168 thrashing rate, respectively ( Fig 4B) . The decreased phenotypic severity of adsl-1(RNAi) likely reflects 169 the incomplete knockdown by RNAi (Fig 2A) . 170 adsl-1(tm3328) animals appear uncoordinated in addition to their sluggish movement. Thus, we 171 measured additional parameters of thrashing animals using ImageJ. The adsl-1(tm3328) animals have a 172 78% reduction in the average speed at which their body bends, consistent with manual counts of thrashing 173 rates ( Fig 4C) . Control N2 animals exhibit an undulatory pattern of locomotion (26,27) with a normally 174 distributed angle of bending intensity around an average of 37.8 while adsl-1(tm3328) animals display a 175 clearly distinct distribution of bend intensities ( Fig 4D) . Mutant animals bend with less intensity relative 176 to N2 controls during the majority of contractions. Despite the preference for these small bends, adsl-177 1(tm3328) are capable of contractions comparable to and beyond that of N2; a small proportion of mutant 178 bends exceed the typical range of bending for N2 controls. Body bends of minimal or maximal intensity 9 in adsl-1(tm3328) deviate greatly from the undulatory bending required for coordinated movement in C. 180 elegans (28,29). We conclude that both pace and quality of muscle contractions is altered in adsl-1 mutant 181 animals. 182 183
Disruption of adsl-1 function affects cholinergic signaling 184
We next considered the question of how disruption of adsl-1 function might result in the observed 185 muscle contraction phenotypes. We investigated the hypotheses that hindered locomotion was caused by 186 either disruption of the cholinergic synaptic transmission, which is required for potentiating action 187 potential firing in body wall muscle, or the reduced response of the muscle cells to this signal (30). We adsl-1(tm3328) displayed mild resistance to levamisole over a five hour period of exposure. Following 24 193 hours of continual exposure, no difference was observed between adsl-1(tm3328) and N2 controls (Fig 194 5A ). Resistance to aldicarb has been shown for mutants in both pre-synaptic and post-synaptic tissue (34). 195 adsl-1(tm3328) displayed a strong resistance to aldicarb over a five hour period of exposure ( Fig 5B) . 196
Following 24 hours of continual exposure, 25% of the adsl-1(tm3328) animals resisted paralysis ( Fig 5B) . 197
We conclude that adsl-1 mutants exhibit a stronger resistance to aldicarb than levamisole. The mild 198 resistance to levamisole may indicate that muscle response is suboptimal. However, the resistance to 199 aldicarb indicates that neural transmission is significantly affected by loss of adsl-1 activity. 200 201 202 203
Reduction of adsl-1 function alters intermediate metabolite levels but has no effect on global purine 204 levels 205
To investigate the hypotheses that changes in ADSL substrate or purine levels are causative of 206 phenotypes, we quantified metabolite levels in adsl-1(RNAi) animals using LC-MS. We specifically 207 measured the levels of both ADSL substrates, SAICAR and S-AMP, in six biological replicate samples of 208 adsl-1(RNAi) and control eri-1 animals. There were no detectable peaks for SAICAR in any of the 209 control RNAi replicates ( Fig 6A) , indicating that the amount of SAICAR is typically below the threshold 210 for metabolite detection via our methods. In all six replicates of adsl-1(RNAi), SAICAR was easily 211 detected ( Fig 6A) , indicating that there is an increase in SAICAR levels when adsl-1 is knocked down. 212
Global levels of S-AMP are also increased in adsl-1(RNAi) compared to the control ( Fig 6B) . This data 213
suggests that knockdown of adsl-1 leads to the accumulation of ADSL substrates, similar to substrate 214 accumulation shown in humans. 215
We also measured global levels of purine monophosphate metabolites in adsl-1(RNAi) and 216 control animals. Interestingly, none of these metabolites showed statistically significant changes upon 217 adsl-1 knockdown. AMP is the only metabolite that shows a downward trend ( Fig 6C) with an average 37% 218 decrease in the adsl-1 samples, relative to controls. Levels of IMP do not exhibit any difference in adsl-219 1(RNAi) compared to the control ( Fig 6D) . Levels of XMP are more variable than that of AMP or IMP, 220 but do not display any relative difference when comparing adsl-1(RNAi) to controls ( Fig 6E) . The 221 relative levels of GMP have the largest variance of the examined metabolites for adsl-1 RNAi, but did not 222 exhibit a statistically significant difference from the control ( Fig 6F) . Overall, this data indicates that there 223 is no significant decrease in purine metabolite levels caused by a knockdown of adsl-1. 224 225
Reduced de novo synthesis contributes to the reproductive phenotype 226
To investigate the potential toxic effects of intermediate metabolite accumulation and the 227 blockage of de novo purine production as causative of phenotypes, we examined the effect of both 228 supplementation with purines and inhibition of substrate production on phenotypic outcome. Even though 229
we detect no global deficit in purine levels, we investigated whether decreased purine production is 230 functionally contributing to the reproductive phenotype by supplementing with purine products. This 231 supplementation strategy would allow the purine salvage pathway to more efficiently compensate for the 232 blockage of de novo biosynthesis. To block substrate accumulation, we used methotrexate, an 233 antimetabolite that inhibits de novo purine biosynthesis upstream of ADSL (35, 36) . 234
Supplementation of cultures with purine products restored fertility in adsl-1(RNAi) animals. 235
Fertility was restored to 90% of animals upon adenosine supplementation and 80% of animals upon 236 guanosine supplementation ( Fig 7A) . Fecundity was also restored by supplementation with purines. 237
Supplementation with adenosine restored fecundity to 65% of control levels and supplementation with 238 guanosine restored fecundity to 62% of control levels (Fig 7B) . Supplementation of cultures with 239 methotrexate had no effect on the fecundity or fertility of adsl-1 RNAi animals ( Fig 7B) ; evidence for the 240 uptake and inhibitory effect of methotrexate is shown below. Thus, the sterility phenotype is linked to a 241 deficit in de novo purine synthesis, and we detected no role for substrate accumulation in the fertility 242 phenotype. 243 244
Substrate buildup contributes to the neuromuscular phenotype 245
We also examined the effect of methotrexate and purine supplementation on the phenotypic 246 outcome of adsl-1(tm3328) and adsl-1(RNAi) animals using thrashing assays. Both adsl-1(tm3328) and 247 adsl-1(RNAi) displayed improved locomotion upon methotrexate supplementation. The supplemented 248 mutants displayed a 212% increase in thrashing rate compared to the control mutants, but are only 249 restored to ~45% of the N2 control ( Fig 8A) . The attenuation of the milder phenotype of adsl-1(RNAi) is 250 more robust than that of the mutants; these animals thrash at a rate indistinguishable from the empty 251 vector control ( Fig 8B) . We then used LC-MS to quantify the effects of methotrexate supplementation on 252 adsl-1(RNAi) animals. As expected, methotrexate supplementation results in a decrease in SAICAR 12 levels in adsl-1(RNAi) animals ( Fig 8C) . In contrast, the minor increase in S-AMP observed in adsl-254 1(RNAi) is not significantly affected by methotrexate supplementation (Fig 8D) . Thus, methotrexate 255 supplementation effectively decreases the accumulation of SAICAR, the first ADSL substrate in the de 256 novo pathway. We also investigated whether a deficit in purine production is functionally contributing to 257 the neuromuscular phenotype, similar to the reproductive phenotype. Supplementation with adenosine, 258 sufficient to restore fertility and fecundity, had no effect on thrashing rate for adsl-1(tm3328) or the N2 259 control ( Fig 8E) . We conclude from these data that SAICAR accumulation likely affects neuromuscular 260 function of adsl-1. 261 262
Discussion

263
We have established C. elegans as an effective model for studying adenylosuccinate lyase 264 deficiency (ASLD). C. elegans with reduced or eliminated function of ADSL have phenotypic and 265 biochemical similarity to the human disorder. In both humans and C. elegans, individuals heterozygous 266 for a mutation in ADSL are phenotypically normal, but homozygous individuals exhibit severe motor and 267 developmental phenotypes (4,9,15). The locomotive defect in C. elegans mimics the muscle ataxia in 268 human patients (15,16). Furthermore, metabolic analysis also shows similar substrate accumulation in 269 whole animal lysates as in human patients (37). Phenotypic similarities were shown to be present in both 270 adsl-1 RNAi and adsl-1(tm3328) homozygotes, creating different genetic techniques to model this 271
disorder. 272
Our observations regarding the sterility phenotype of adsl-1 revealed disruption of both 273 gonadogenesis and oogenesis. We found that the development of the gonad is severely hindered for both Given that the RNAi knockdown is incomplete, we conclude that the reproductive system is quite 279 sensitive to the level of adsl-1 activity for proper development. 280
Embryonic development is also sensitive to levels of adsl-1 activity. We can avoid the typical 281 sterility of adsl-1(RNAi) by administering the RNAi following larval development. Under these 282 conditions, there is significant embryonic lethality associated with adsl-1(RNAi). We also demonstrated a 283 developmental defect in the adsl-1(tm3228) mutants as evidenced by the deficit in homozygous mutants 284 from the progeny of the balanced heterozygotes. However, this defect cannot be specifically linked to 285 embryonic development. The fluorescent marker associated with the balancer is not visible in eggs, 286 preventing selection of homozygous mutant eggs from the progeny pool. Embryonic lethality is likely to 287 contribute to lethality of adsl-1(tm3328) as it does for adsl-1(RNAi), but the possibility remains that post-288 embryonic lethality or failure of mutant oocytes to mature contributes to the deficit of tm3328 289 homozygotes in the balanced strain. 290
adsl-1 animals are slow and display an irregular pattern of movement, mimicking the phenotypic 291 outcome for ASLD in humans. Our data suggest a flaw in the muscle activation strategy behind the 292 sinusoidal motion of C. elegans (38). While locomotion was slowed for both adsl-1(tm3328) and adsl-293 1(RNAi), the phenotype was more severe in adsl-1(tm3328) mutants. The milder locomotory phenotype 294 of adsl-1(RNAi) likely reflects more residual enzyme activity and a less stringent requirement for high 295 ADSL activity in locomotion compared to gonadogenesis and fertility. Nevertheless, adsl-1(RNAi) is an 296 excellent model of the human syndrome, paralleling both a level of residual gene activity and a 297 neuromuscular phenotype. 298
Given the evidence for a disruption in the patterning of muscle activation during locomotion, we 299 investigated cholinergic signaling as a possible cause for this locomotive phenotype. A moderate 300 resistance to levamisole in the adsl-1 mutants indicates a variation in post-synaptic body wall function. 301
Because levamisole can only stimulate the muscle tissue, we suggest that the resistance must arise from a 302 defect in cholinergic receptors or the initiation of the contraction within the muscle itself. This assay 303 14 reveals a tissue target that is involved in the locomotive phenotype. However, the more prominent 304 resistance to aldicarb provides additional insight. Resistance to aldicarb can arise from defects in pre-305 synaptic acetylcholine release or from the post-synaptic cholinergic response. Because our levamisole 306 assay exposed an issue with post-synaptic tissue, we examined the aldicarb resistance with this in mind. 307 adsl-1 mutants paralyze much slower on aldicarb and are capable of resisting paralysis past 24 hours of 308 exposure. Because the aldicarb paralysis curve does not resemble that of levamisole, we conclude that 309 there are additional factors contributing to the aldicarb resistance in pre-synaptic cholinergic neurons. 310
This finding suggests that altered neuromuscular transmission may contribute to the muscular ataxia 311 observed in ADSL patients. 312
By measuring metabolite levels for adsl-1(RNAi) animals, we have established that knockdown 313 of adsl-1 in C. elegans also results in metabolic similarity to the human syndrome. We did not measure 314 metabolite levels in mutant strain because the sterility and developmental lethality associated with adsl-315 1(tm3328) prevents us from obtaining the large population of homozygous mutants required for LC-MS 316 analysis. In addition to the limitations of the mutant strain, adsl-1(RNAi) was chosen for metabolomics 317 analysis because this treatment is predicted to best model the human syndrome. The accumulation of the 318 biosynthetic intermediates SAICAR and S-Ado during knockdown of adsl-1 closely resembles the 319 SAICAr and S-Ado accumulation observed across numerous human patients and tissue samples (3,6,11). 320
As such, adsl-1 knockdown in C. elegans mimics the primary diagnostic biochemical markers of ASLD 321 in humans. 322
Interestingly, knockdown of adsl-1 did not significantly affect any of the purine monophosphate 323 products of de novo synthesis. The salvage biosynthesis pathways likely contribute to homeostatic 324 mechanisms that maintain global purine levels in the absence of efficient de novo synthesis. It is likely 325 that these animals are recycling enough purines from their diets to accommodate for the blockage of de 326 novo biosynthesis but this model remains to be tested. Our metabolite measurements are derived from 327 mixed-stage, whole-animal lysates. Thus, it remains possible that certain cells, tissues or developmental 328 stages do not successfully maintain purine levels. Increased demand for purines or low activity of the 329 salvage enzymes could alter purine levels for specific cells or developmental stages; more affected cell 330 types could be masked by the whole-animal scale of metabolite measurements. Even with this possibility, 331 the global maintenance of purine monophosphate levels still suggests compensation for the blockage of 332 de novo synthesis in adsl-1(RNAi) animals. This maintenance of global purine levels is consistent with 333 previous findings for adenine and guanine concentrations in patients and disease models with decreased 334 ADSL function (13,21). Once again, metabolic profiling of adsl-1(RNAi) in C. elegans mimics the 335 findings for human patients with decreased ADSL function, indicating the effectiveness of this model for 336 studying ASLD. 337
Supplementation with individual purine products results in restoration of fertility. Each 338 supplement can be converted to IMP, the central metabolite of purine synthesis, through the salvage 339 pathways. In this way, these supplementations can overcome the blockage of IMP biosynthesis that 340 results from the first function of ADSL, conversion of SAICAR to AICAR. However, adenosine is the 341 only supplement that overcomes the second blockage of ADSL function, conversion of S-AMP to AMP. 342
For this reason, it is interesting that both of the tested purine supplements are able to independently 343 reverse the sterility of adsl-1(RNAi). We observed that adenosine supplementation is more robust than 344 guanosine, but guanosine is still capable of restoring fertility to a significant extent. This result suggests 345 that compensation for the second enzymatic function of ADSL is not as crucial for restoring fertility to 346 adsl-1(RNAi) or that residual levels of ADSL-1 more easily suffice for this biochemical step. 347
Fertility restoration upon purine product supplementation indicates that a decrease in de novo 348 purine production contributes to this phenotype. Furthermore, the correlation of sterility to the blockage 349 of de novo synthesis is also predicted to be related to a potential increased demand for purines during the 350 rapid division in gonad development when germ cells are dividing. A high demand for purines during 351
reproductive development may cause a gonad-specific deficit of purines that is not reflected through 352 metabolomics analysis for whole animal lysates of mixed age. Due to the severity of ASLD in humans, 353 reproduction is not an option, so any direct correlation with the reproductive phenotype is unknown. 354
Despite this, the linkage of a phenotype to a blockage of de novo purine formation in C. elegans indicates 355 some of the human symptoms may have the same linkage. For this reason, one possible therapeutic 356 approach to ASLD would be to supplement additional purines to the diets of affected individuals in 357 combination with a block to purine biosynthesis. 358
Our finding that methotrexate supplementation alleviates the locomotive defect for both adsl-359 1(tm3328) and adsl-1(RNAi) suggests that substrate accumulation is causative of this phenotype. 360
Metabolomics analysis of adsl-1(RNAi) specifically suggests that SAICAR accumulation is causative of 361 this neuromuscular phenotype. Although methotrexate is capable of improving the locomotion of adsl-362 1(RNAi) to that of the empty vector control, methotrexate does not fully ameliorate the locomotive 363 phenotype of adsl-1(tm3328). It is possible that SAICAR accumulates to a greater extent in adsl-364 1(tm3328) than adsl-1(RNAi). In this case, methotrexate supplementation may not reduce SAICAR levels 365 enough to fully attenuate the severe locomotive phenotype of adsl-1(tm3328). Metabolomics analysis of 366 adsl-1(tm3328) could reveal if this is the case, but is not technically feasible at this time. 367
The correlation between SAICAR accumulation and the locomotive defect is particularly 368 interesting due to phenotypic similarity to muscular ataxia in humans. Because of this correlation, our 369 data suggests that the motor control of humans may be improved by blocking SAICAR accumulation in a 370 similar manner. The high conservation of purine biosynthesis indicates that a therapeutic approach using 371 de novo synthesis inhibition could alleviate symptoms in humans. While these results expand on the 372 relevance of SAICAR accumulation to phenotype, this study provides a crucial role in understanding the 373 linkage between metabolic disturbance and disorder phenotype. Strains were maintained on OP50 Escherichia coli as food under standard conditions at 20º C (39). We 380 used the following strains; N2, eri-1(mg366), and adsl-1(tm3328) . The N2 and GR1373 eri-1(mg366) 381 strains were obtained from the Caenorhabditis Genetics Center (CGC). adsl-1(tm3328) was obtained from 382 the National BioResource Project in Tokyo, Japan and outcrossed three times against N2 The outcrossed, 383 balanced strain was named HV854. This allele is homozygous sterile and was balanced with hT2, a 384 balancer for the first and third chromosomes of C. elegans; this balancer causes pharyngeal expression of 385 GFP (40). Non-GFP homozygous adsl-1(tm3328) animals were used in phenotypic analysis. 386
387
RNAi 388 The adsl-1 RNAi clone was from the C. elegans RNAi Library (Source BioScience, Nottingham, UK).
389
RNAi feeding assays were carried out as described (23). Unless otherwise noted, we transferred mid-L4 390 eri-1 animals to RNAi plates and examined their progeny in assays. E. coli strain HT115 carrying the 391 empty RNAi feeding vector (EV) L4440 was used as a control. 392 393
Metabolite Supplementation
394
We prepared filter-sterilized stock solutions of 22 mM methotrexate (Sigma) in DMSO and stock 395 solutions of 117 mM adenosine (Sigma) in H 2 O with 10% 1 M NaOH and 150 mM guanosine (Sigma) in 396 H 2 O with 25% 1 M NaOH. We added these solutions to OP50 seeded NGM plates to a final concentration 397 of 22 µM methotrexate and 10 mM adenosine, guanosine. Following supplementation, we incubated the 398 plates at room temperature for 1-2 days before use. After 1 minute of acclimation at room temperature, thrashes, the number of body bends, were counted for 446 1 minute using a Nikon SMZ645 Stereoscope. 447 448 Bending Quantification. Individual animals were aged and placed in M9 solution following the same 449 procedure as the thrashing assay. 30 second videos were collected on a Nikon SMZ1500 Stereoscope 450 20 using NIS-Elements software from Nikon. Videos were analyzed using ImageJ to create ideal conditions 451 for computer-based quantification of C. elegans locomotion. First, the video background was subtracted 452 using the rolling ball method. The background of each video is unchanging, allowing the starting frame to 453 be subtracted from all frames. The videos were then converted to binary by setting a threshold with the 454 "Otsu" thresholding algorithm. Binary videos of animals were processed through the wrMTrck plugin for 455
ImageJ. Raw data of bending angle was obtained in the BendCalc format with bendDetect set to angle; 456 this data provides bending angle for an animal at each frame of a video. 457
Raw data for the rate of change in bending angle were provided on a frame by frame basis for 458 each video. The magnitude of these values were averaged to determine the bending speed for each animal; 459 absolute magnitude was used to combine abduction and adduction into one dataset for all types of 460 bending. Data points for the maximum bending extent were manually selected from raw data sets for each 461 animal. The extent of each bend was determined by recording the value at each local maximum and 462 minimum. These turning points represent the most extreme point in a bend before movement back to the 463 mid-line of the animal. The absolute value of each bend was used for calculation of bending extent for 464 each animal. 465 466 Paralysis. Two days prior to the assay, we added aldicarb (Sigma) or levamisole (Sigma) to unspotted 467 NGM plates to a final concentration of 1 mM. We allowed the plates to dry at room temperature 468 overnight then moved them to 4º C until the time of the assay. Approximately 20 mid-L4 hermaphrodites 469 of each genotype were aged for 1 day at 20º C prior to the assay. We placed a 10 µl spot of OP50 E. coli 470 solution on each plate and allowed it to dry for 30 minutes, concentrating the animals in a small area. 471
Animals of a single genotype were placed on to an aldicarb plate and scored for paralysis every 30 472 minutes as described (34). 473 474 21 Egg-laying. For the egg-laying assay, ten eri-1 animals were placed on a plate containing the desired 475 RNAi and supplementation. For each condition, ten second generation mid-L4 animals were placed onto 476 individual plates. The number of eggs laid by each animal was counted over a five day period. 477 478 Statistical Analysis 479 Two-tailed student t tests were used to determine p values when comparisons were limited between two 480 conditions. One-way or two-way ANOVA was carried out with appropriate post-tests to determine p 481 values between three or more experimental conditions. In LC-MS analysis, we used Welch's two sample t 482 test to calculate p values. We substituted all undetectable measurements with zeros to statistically 483 compare conditions for LC-MS. In all figures: ns, not significant; *, 0.01 <p< 0.05; **, 0.001<p< 0.01; 484 ***, p<0.001; ****, p<0.0001. 
